US Stock MarketDetailed Quotes
ENLV Enlivex Therapeutics
- 1.140
- +0.070+6.54%
Close Nov 27 16:00 ET
- 1.120
- -0.020-1.75%
Post 20:01 ET
24.40MMarket Cap-966P/E (TTM)
1.160High1.100Low259.76KVolume1.150Open1.070Pre Close298.06KTurnover1.67%Turnover RatioLossP/E (Static)21.41MShares4.59052wk High0.85P/B17.73MFloat Cap0.81052wk Low--Dividend TTM15.55MShs Float44.900Historical High--Div YieldTTM5.61%Amplitude0.810Historical Low1.147Avg Price1Lot Size
About Enlivex Therapeutics Company
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Company Profile
SymbolENLV
Company NameEnlivex Therapeutics
Listing DateJul 31, 2014
Issue Price11.00
Founded2012
CEOMr. Oren Hershkovitz, PhD
MarketNASDAQ
Employees49
Fiscal Year Ends12-31
Address14 Einstein Street
CityNess Ziona
ProvinceTel Aviv
CountryIsrael
Zip Code7403618
Phone972-8-662-3301
Websitehttp://www.enlivex.com
Company Executives
- Name
- Position
- Salary
- Oren Hershkovitz, PhD
- Chief Executive Officer
- --
- Shachar Shlosberger, C.P.A.
- Chief Financial Officer
- --
- Dr. Roger J. Pomerantz, F.A.C.P.,M.D.
- Vice Chairman of the Board
- --
- Shai Novik, M.B.A.
- Executive Chairman of the Board
- --
- Dr. Brian Schwartz, M.D.
- Director
- --
- Dr. Abraham Havron, PhD
- Independent Director
- --
- Andrew E. Singer
- Independent Director
- --
- Dr. Gili Hart, PhD
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data